SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

1. Name and Address of Reporting Person* Sanders Walter Lloyd (Last) (First) (Middle) 320 WAKARA WAY (Street) SALT LAKE CITY UT 84108 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 08/01/2018	3. Issuer Name and Ticker or Trading Symbol MYRIAD GENETICS INC [ MYGN ]
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) President Myriad Oncology	5. If Amendment, Date of Original Filed (Month/Day/Year)
			6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	24,961	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Incentive Stock Option (right to buy)	09/17/2017	09/17/2021	Common Stock	3,775	26.49	D
Incentive Stock Option (right to buy)	09/12/2016	09/12/2022	Common Stock	3,694	27.07	D
Non-Qualified Stock Option (right to buy)	09/17/2017	09/17/2021	Common Stock	16,850	26.49	D
Non-Qualified Stock Option (right to buy)	09/12/2016	09/12/2022	Common Stock	5,056	27.07	D

Explanation of Responses:

	By: Richard Marsh For: Walter Sanders	08/03/2018
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY


Know all by these presents, that the undersigned
hereby constitutes and appoints each of Richard
M. Marsh, R. Bryan Riggsbee and Nathan A. Smith
of Myriad Genetics, Inc. the Company, and Jonathan
L. Kravetz, Daniel Follansbee and Pamela Greene of
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.,
signing singly, with full power of substitution,
the undersigned s true
and lawful attorney-in-fact to:

1	execute for and on behalf of the undersigned,
forms and authentication documents for EDGAR Filing Access;

2	do and perform any and all acts for and
on behalf of the undersigned which may be necessary
or desirable to complete and execute any such forms
and authentication documents;

3	execute for and on behalf of the undersigned,
in the undersigned's capacity as an officer, director
and/or 10% shareholder of the Company,
Forms 3, 4 and 5 in accordance with Section
16a of the Securities Exchange Act of 1934 and the
rules thereunder;

4	do and perform any and all acts for and on
behalf of the undersigned which may be necessary
or desirable to complete and execute any such
Form 3, 4 or 5 and timely file such form with
the United States Securities and Exchange Commission
and any stock exchange or similar authority; and

5	take any other action of any type whatsoever
in connection with the foregoing which, in the opinion
of such attorney-in-fact, may be of benefit to, in the
best interest of, or legally required by, the undersigned,
it being understood that the documents executed by
such attorney-in-fact, on behalf of the undersigned
pursuant to this Power of Attorney, shall be in such
form and shall contain such terms and conditions
as such attorney-in-fact may approve in such
attorney-in-fact s discretion.

The undersigned hereby grants to each such
attorney-in-fact full power and authority
to do and perform any and every act and
thing whatsoeverrequisite, necessary, or
proper to be done in the exercise of any
of the rights and powers herein granted,
as fully to all intents and purposes
as the undersigned might or could do if personally
present, with full power of substitution or
revocation, hereby ratifying and confirming all
that such attorney-in-fact, or such attorney-in-facts
substitute or substitutes, shall lawfully do or cause
 to be done by virtue of this power
of attorney and the rights and powers herein granted.
The undersigned acknowledges that the foregoing
attorneys-in-fact, in serving in such
capacity at the request of the undersigned, is
not assuming, nor is the Company assuming, any
of the undersigned's responsibilities to comply
with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force
and effect until the undersigned is no longer
required to file Forms 3, 4 and 5 with respect
to the undersigned's holdings of and transactions
in securities issued by the Company, unless
earlier revoked by the undersigned in a signed
writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused
this Power of Attorney to be executed this
13th day of July, 2018.

/s/ Walter Lloyd Sanders

Walter Lloyd Sanders